The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
Open accessAbstract
BACKGROUND: Survivin is expressed in prostate cancer (PCa), and its downregulation sensitizes PCa cells to chemotherapeutic agents in vitro and in vivo. Small membrane-bound vesicles called exosomes, secreted from the endosomal membrane compartment, contain RNA and protein that they readily transport via exosome internalization into recipient cells. Recent progress has shown that tumor-derived exosomes play multiple roles in tumor growth and metastasis and may produce these functions via immune escape, tumor invasion and angiogenesis. Furthermore, exosome analysis may provide novel biomarkers to diagnose or monitor PCa treatment. METHODS: Exosomes were purified from the plasma and serum from 39 PCa patients, 20 BPH patients, 8 prostate cancer recurrent and 16 healthy controls using ultracentrifugation and their quantities and qualities were quantified and visualized from both the plasma and the purified exosomes using ELISA and Western blotting, respectively. RESULTS: Survivin was significantly increased in the tumor-derived samples, compared to those from BPH and controls with virtually no difference in the quantity of Survivin detected in exosomes collected from newly diagnosed patients exhibiting low (six) or high (nine) Gleason scores. Exosome Survivin levels were also higher in patients that had relapsed on chemotherapy compared to controls. CONCLUSIONS: These studies demonstrate that Survivin exists in plasma exosomes from both normal, BPH and PCa subjects. The relative amounts of exosomal Survivin in PCa plasma was significantly higher than in those with pre-inflammatory BPH and control plasma. This differential expression of exosomal Survivin was seen with both newly diagnosed and advanced PCa subjects with high or low-grade cancers. Analysis of plasma exosomal Survivin levels may offer a convenient tool for diagnosing or monitoring PCa and may, as it is elevated in low as well as high Gleason scored samples, be used for early detection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Exosomal-like vesicles are present in human blood plasma
Caby, M.-P., Lankar, D., Vincendeau-Scherrer, C., Raposo, G., & Bonnerot, C. (2005) · International Immunology · doi:10.1093/intimm/dxh267 · Cited by 1,343
Survivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Exosome Release Is Regulated by a Calcium-dependent Mechanism in K562 Cells
Savina, A., Furlán, M., Vidal, M., & Colombo, M. I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301642200 · Cited by 834
HAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)63946-8 · Cited by 679
HAN, M., PARTIN, A. W., ZAHURAK, M., PIANTADOSI, S., EPSTEIN, J. I., & WALSH, P. C. (2003) · The Journal of Urology · doi:10.1097/00005392-200302000-00018 · Cited by 638
Bhatnagar, S., Shinagawa, K., Castellino, F. J., & Schorey, J. S. (2007) · Blood · doi:10.1182/blood-2007-03-079152 · Cited by 633
Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A. S., Sauvageot, J., Song, K. B., Kitada, S., & Reed, J. C. (1996) · Europe PMC (PubMed Central) · Cited by 593
Nakahara, T., Takeuchi, M., Kinoyama, I., Minematsu, T., Shirasuna, K., Matsuhisa, A., Kita, A., Tominaga, F., Yamanaka, K., Kudoh, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1343 · Cited by 497
Tumour-released exosomes and their implications in cancer immunity
Iero, M., Valenti, R., Huber, V, Filipazzi, P., Parmiani, G., Fais, S., & Rivoltini, L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402237 · Cited by 485
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Induction of heat shock proteins in B-cell exosomes
Clayton, A., Turkes, A., Navabi, H., Mason, M. D., & Tabi, Z. (2005) · Journal of Cell Science · doi:10.1242/jcs.02494 · Cited by 454
Tumor-Released Microvesicles as Vehicles of Immunosuppression
Valenti, R., Huber, V., Iero, M., Filipazzi, P., Parmiani, G., & Rivoltini, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0520 · Cited by 409
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Exosomes biological significance: A concise review
Johnstone, R. M. (2006) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2005.12.001 · Cited by 339
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00388-5 · Cited by 339
Can urinary exosomes act as treatment response markers in prostate cancer?
Mitchell, P. J., Welton, J., Staffurth, J., Court, J., Mason, M. D., Tabi, Z., & Clayton, A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-4 · Cited by 313
Exosomes as Biomarker Treasure Chests for Prostate Cancer
Duijvesz, D., Luider, T., Bangma, C. H., & Jenster, G. (2011) · European Urology · doi:10.1016/j.eururo.2010.12.031 · Cited by 278
Elevated expression of inhibitor of apoptosis proteins in prostate cancer.
Krajewska, M., Krajewski, S., Banares, S., Huang, X., Turner, B., Bubendorf, L., Kallioniemi, O., Shabaik, A. S., Vitiello, A., Peehl, D. M., et al. (2003) · PubMed · Cited by 275
Survivin is released from cancer cells via exosomes
Khan, S., Jutzy, J. M. S., Aspe, J. R., McGregor, D. W., Neidigh, J. W., & Wall, N. R. (2011) · Apoptosis · doi:10.1007/s10495-010-0534-4 · Cited by 265
Self-citationKoumangoye, R. B., Sakwe, A. M., Goodwin, J. S., Patel, T., & Ochieng, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024234 · Cited by 227
Survivin mediates resistance to antiandrogen therapy in prostate cancer
Zhang, M., Latham, D. E., Delaney, M. A., & Chakravarti, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208490 · Cited by 223
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
Tumor markers in prostate cancer I: Blood-based markers
Shariat, S. F., Semjonow, A., Lilja, H., Savage, C., Vickers, A. J., & Bjartell, A. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.542174 · Cited by 174
Khan, S., Aspe, J. R., Asumen, M. G., Almaguel, F. A., Odumosu, O., Acevedo-Martinez, S., León, M. A. D., Langridge, W. H. R., & Wall, N. R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604978 · Cited by 160
Self-citationThe immunogenicity of dendritic cell-derived exosomes
Quah, B., & O'Neill, H. C. (2005) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2005.05.002 · Cited by 149
Urine biomarkers in prostate cancer
Ploussard, G., & TAILLE, A. D. L. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2009.261 · Cited by 137
Li, Y., Che, M., Bhagat, S., Ellis, K.-L., Küçük, Ö., Doerge, D. R., Abrams, J., Cher, M. L., & Sarkar, F. H. (2004) · Neoplasia · doi:10.1593/neo.03478 · Cited by 111
Are multiple markers the future of prostate cancer diagnostics?
Mikolajczyk, S. D., Song, Y. S., Wong, J. R., Matson, R. S., & Rittenhouse, H. G. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.016 · Cited by 79
Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers
Bjartell, A. S., Montironi, R., Berney, D. M., & Egevad, L. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.531284 · Cited by 61
Screening for prostate cancer with PSA testing: current status and future directions.
Croswell, J. M., Kramer, B. S., & Crawford, E. D. (2011) · PubMed · Cited by 61
Blood and Tissue Biomarkers in Prostate Cancer: State of the Art
Fiorentino, M., Capizzi, E., & Loda, M. F. (2010) · Urologic Clinics of North America · doi:10.1016/j.ucl.2009.11.006 · Cited by 38
Localized prostate cancer: radiation or surgery?
Klein, E. A., & Kupelian, P. A. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(02)00179-9 · Cited by 28
Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.010 · Cited by 21
Cited by
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Exosomes in cancer: small particle, big player
Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0181-x · Cited by 780
Kanwar, S. S., Dunlay, C. J., Simeone, D. M., & Nagrath, S. (2014) · Lab Chip · doi:10.1039/c4lc00136b · Cited by 662
Exosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
Maacha, S., Bhat, A. A., Jimenez, L., Raza, A., Haris, M., Uddin, S., & Grivel, J.-C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0965-7 · Cited by 572
Metadata
- Authors
- Khan, S., Jutzy, J. M. S., Valenzuela, M. M. A., Turay, D., Aspe, J. R., Ashok, A., Mirshahidi, S., Mercola, D., Lilly, M. B., & Wall, N. R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-16
- Volume
- 7
- Issue
- 10
- Pages
- e46737
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1970420774
- Cited by
- 331
- References
- 35
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.